BTK inhibitor (Generation II) project Introduction
2016-12-14
The advantage of project：
Ø Preliminary experiments showed that ZXBT-1158 was safer and more effective than the parent compound ACP-196.
Ø Various indications are effective for B-cell malignant tumors, solid tumors and autoimmune diseases.
Ø Inhibition of BTK selectivity is better, avoiding or reducing some of the adverse reactions associated with cancer treatment.
Ø Clinically, individualized treatment can be carried out in combination with the level of BTK.
Ø Oral medicine, easy to take.
